Pioneering aesthetic treatments

From the start, innovation has been at the heart of everything we do at Galderma. We help patients realize their own individual beauty goals by continuously developing new technologies and techniques that are clinically proven and effective.

Our innovative filler technologies

When Restylane® was launched more than 27 years ago, it was the first non-animal stabilized hyaluronic acid- based dermal filler, created for reliable aesthetic treatments and with a proven safety record.1,2 Since then, we have continued to develop innovative dermal filler products.

Today, dermal fillers with hyaluronic acid are not only used to fill out lines and wrinkles, but also to create volume, for example in the cheeks and lips, and to enhance facial shape and lift areas, such as the chin and jawline.

To cater for all of these new uses, Galderma has developed three different technologies—NASHA® HD™, NASHA® and OBT™ that offer everything from structural support to natural expression and a healthy glow.3-8 With different technologies and gel consistencies, healthcare practitioners have all the tools they need to provide patients with truly individualized and tailored results.

Our innovations for improving 
skin quality

As we age, or due to a harsh environment, multiple internal and external factors can lead to a visible decline in the skin’s appearance, such as more prominent nasolabial folds and sagging skin.9
‍
To treat these changes, we have developed two different solutions that directly target the cause of the deterioration of skin quality—Sculptra® and Restylane® Skinboosters™.10,11



Sculptra® is the first proven regenerative biostimulator that addresses multiple skin concerns and is made with the unique PLLA-SCA™ formulation.10,12-16 The treatment can be tailored to suit different patient needs.

Restylane® Skinboosters™ was the first product of its kind on the market, utilizing a new and innovative method to improve skin hydration from within. Restylane® Skinboosters™ can significantly improve skin elasticity, reduce fine lines and improve the overall appearance of the face.17,18

Other innovative solutions in 

our portfolio

Sometimes, the appearance of glabellar lines (frown lines) and crow’s feet can cause our faces to look old, sad, tired or angry, regardless of how we feel.19,20 We provide healthcare practitioners with botulinum toxin products that can be used to relax facial muscles that are responsible for the formation of dynamic wrinkles.

Furthermore, we have a strong focus on facilitating treatment procedures for healthcare practitioners, by developing innovative and ergonomically designed tools and systems. For example, Restylane® Skinboosters™’ award-winning SmartClick™ System improves dosing accuracy of stabilized hyaluronic acid for consistent results, and its audible feedback system increases safe use.21

Most diverse portfolio of injectable technologies

27+

years of aesthetic innovation2

85+

million treatments worldwide1,22,23

References

1. Galderma. Data on file. MA-39680. Global 55 million Restylane® treatments, update 2022. 2. Galderma. Data on file. MA-55607. Restylane® 27 years data publications analysis, 2023.
3. Metelitsa A et al. J Cosmet Dermatol. 2024;23(5):1604–12. 4. Öhrlund A et al. J Drugs Dermatol. 2024;23(1):1332–6. 5. Rogerio V et al. J Stomatol Oral Maxillofac Surg. 2022;123(4):
440–7. 6. Di Gregorio C et al. Clin Cosmet Investig Dermatol. 2022;14:681–90. 7. Dierickx C et al. Dermatol Surg. 2018;44 Suppl. 1:S10–8. 8. Galderma. Data on file. MA-56724 X-strain and G' including Shaype. [PLACEHOLDER to be replaced with full publication once available]. 9. Hexsel D, et al. Dermatol Surg. 2020;46(8):1122–4. 10. Sculptra® IFU. EU. 11. Restylane® SKINBOOSTERS™ IFU. EU. 12. Galderma Receives FDA Approval for New SCULPTRA® Label, Offering More Options to Aesthetic Partners. Galderma. 2021. Available from: https://www.galderma.com/news/galderma-receives-fda-approvalnew- sculptra-label-offering-more-options-aesthetic-partners [Last accessed June 2024]. 13. Asius J, et al. US patent US 7,731,758 B22(010):2010. 14. Sanofi S.r.l. DEKRA EN ISO 13485:2016 Certificate. Certificate effective since: February 2023. 15. Zhang Y, et al. Regen Biomater 2021;8(5):rbab042.
16. Widgerow A, et al. A randomized, comparative study describing the gene signatures of poly-l-lactic acid (PLLA-SCA) and calcium hydroxylapaptite (CaHA) in the treatment of nasolabial folds. Poster presented at the International Master Course on Aging Science (IMCAS) World Congress. 1–3 February 2024. 17. Gubanova EI et al. Poster presented at IMCAS 2015. 18. Distante F et al. Dermatol Surg 2009;35(S1):389–93. 19.  Finn CJ et al. Dermatol Surg 2003;29(5):450–455. 20. Carruthers A et al. J Cosmet Laser Ther 2007;9 (Suppl 1):6–10.
21.  Red Dot - SmartClick System. Available at: https://www.red-dot.org/project/smartclicktm-system-32176/. Accessed: July 2019. 22. Data on file (MA-40221). 23. Data on file (MA-39613)

Always consult a healthcare professional for individualized treatment recommendations and to

discuss important safety information and risks associated with the use of the products.
Find a specialist
TERMS OF USE
Privacy
Cookie notice